Phuturdex › Diseases › Osteosarcoma
Drugs in development · updated 30 October 2026
Osteosarcoma: drugs in development
As of 30 October 2026 there are 82 active clinical trials (recruiting or ongoing, phases I–III) on 101 drugs for osteosarcoma. 35 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DoxorubicinAdriamycin, Doxorubincin | III | 4 | NCT00470223 |
| EtoposideAvopef®, Etopophos Preservative Free® | III | 4 | NCT00470223 |
| Ifosfamide | III | 4 | NCT00470223 |
| MethotrexateJylamvo®, Reditrex® | III | 4 | NCT00470223 |
| CisplatinCis Platinum, Cisplatine | III | 3 | NCT00470223 |
| Zoledronic AcidZoledronate, Zoledronic acide | III | 3 | NCT00470223 |
| TriptorelinTriptorelin Embonate, Triprorelin Acetate | III | 1 | NCT05328258 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 11 | NCT07321912 |
| FludarabineFludara, FLUDARABIN | II | 7 | NCT07428993 |
| CabozantinibResniben®, Cabometyx® | II | 5 | NCT05019703 |
| NivolumabOpdivo, ONO-4538 | II | 5 | NCT06638931 |
| PembrolizumabKEYTRUDA, MK-3475 | II | 5 | NCT05182164 |
| TemozolomideTemodal, Temodar | I–II | 4 | NCT06541262 |
| VincristineVincristin, Oncovin [vincristine] | I–II | 4 | NCT06541262 |
| GemcitabineGemcitabin, Gemzar | I–II | 3 | NCT03598595 |
Sorted by most advanced phase and number of active trials. Showing 15 of 66 drugs.
All 101 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Ewing sarcoma 82 drugs
- Sarcoma 204 drugs
- Neuroblastoma 95 drugs
- Desmoplastic small-round-cell tumor 19 drugs
- Metastasis 493 drugs
- Rhabdomyosarcoma 68 drugs
- Hepatoblastoma 41 drugs
- Medulloblastoma 77 drugs
- Neoplasm 671 drugs
- Wilms Tumor 37 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Central nervous system neoplasm 70 drugs
Broader categories
- Neoplasm 671 drugs
- Sarcoma 204 drugs
- Nerve tissue neoplasm 4 drugs
- Glandular and epithelial neoplasm 12 drugs
- Neuroectodermal tumor 3 drugs
- Germ cell and embryonal neoplasms 35 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012516 “Osteosarcoma”. Prevalence: Orphanet.